Cortexyme, Inc. (CRTX)
Price:
1.95 USD
( + 0.05 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
NEWS
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
investorplace.com
2022-03-15 12:56:51Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today appeared first on InvestorPlace.
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
benzinga.com
2022-03-08 11:27:00Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
seekingalpha.com
2022-02-28 21:15:15COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
zacks.com
2022-02-18 11:39:40Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)
zacks.com
2022-02-02 11:33:14The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
investorplace.com
2022-02-01 11:36:36Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI appeared first on InvestorPlace.
Cortexyme Stock Sinks After FDA Puts Application on Hold
schaeffersresearch.com
2022-01-26 15:21:48Cortexyme Inc (NASDAQ:CRTX) is plummeting today, last seen down 31.1% at $6.25, after the U.S. Food and Drug Administration (FDA) placed the company's application to start a study of its lead drug for Alzheimer's disease on hold.
Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND
benzinga.com
2022-01-26 09:13:01The Company plans to provide additional updates pending continued engagement with FDA.
Why Cortexyme Stock Imploded in 2021
fool.com
2022-01-12 10:00:00A key clinical setback sent investors to the exits last year.
3 Most-Shorted Stocks at 52-Week Lows to Buy
investorplace.com
2022-01-07 15:21:09In a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors. The post 3 Most-Shorted Stocks at 52-Week Lows to Buy appeared first on InvestorPlace.
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
investorplace.com
2021-12-17 13:50:21Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 appeared first on InvestorPlace.
Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
seekingalpha.com
2021-12-15 15:46:12CRTX reported partially promising results on October 26, 2021, which have been perceived as a complete failure by the market.
5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard
benzinga.com
2021-12-06 10:00:46Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.
Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?
zacks.com
2021-12-01 10:44:19Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
Cortexyme: A Challenging Path Forward
seekingalpha.com
2021-11-17 00:06:49Cortexyme: A Challenging Path Forward
Why Are Cortexyme Shares Falling Today?
benzinga.com
2021-11-11 12:54:09Cortexyme Inc (NASDAQ: CRTX) has presented additional data from its Phase 2/3 GAIN Trial at the Clinical Trials on Alzheimer's Disease Conference. The 643-participant 48-week GAIN Trial failed to meet statistical significance on its co-primary cognitive and functional endpoints in the overall cohort.
No data to display
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
investorplace.com
2022-03-15 12:56:51Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today appeared first on InvestorPlace.
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
benzinga.com
2022-03-08 11:27:00Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
seekingalpha.com
2022-02-28 21:15:15COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
zacks.com
2022-02-18 11:39:40Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)
zacks.com
2022-02-02 11:33:14The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
investorplace.com
2022-02-01 11:36:36Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI appeared first on InvestorPlace.
Cortexyme Stock Sinks After FDA Puts Application on Hold
schaeffersresearch.com
2022-01-26 15:21:48Cortexyme Inc (NASDAQ:CRTX) is plummeting today, last seen down 31.1% at $6.25, after the U.S. Food and Drug Administration (FDA) placed the company's application to start a study of its lead drug for Alzheimer's disease on hold.
Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND
benzinga.com
2022-01-26 09:13:01The Company plans to provide additional updates pending continued engagement with FDA.
Why Cortexyme Stock Imploded in 2021
fool.com
2022-01-12 10:00:00A key clinical setback sent investors to the exits last year.
3 Most-Shorted Stocks at 52-Week Lows to Buy
investorplace.com
2022-01-07 15:21:09In a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors. The post 3 Most-Shorted Stocks at 52-Week Lows to Buy appeared first on InvestorPlace.
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
investorplace.com
2021-12-17 13:50:21Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 appeared first on InvestorPlace.
Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
seekingalpha.com
2021-12-15 15:46:12CRTX reported partially promising results on October 26, 2021, which have been perceived as a complete failure by the market.
5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard
benzinga.com
2021-12-06 10:00:46Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.
Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?
zacks.com
2021-12-01 10:44:19Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
Cortexyme: A Challenging Path Forward
seekingalpha.com
2021-11-17 00:06:49Cortexyme: A Challenging Path Forward
Why Are Cortexyme Shares Falling Today?
benzinga.com
2021-11-11 12:54:09Cortexyme Inc (NASDAQ: CRTX) has presented additional data from its Phase 2/3 GAIN Trial at the Clinical Trials on Alzheimer's Disease Conference. The 643-participant 48-week GAIN Trial failed to meet statistical significance on its co-primary cognitive and functional endpoints in the overall cohort.